Yale School of Medicine

Dermatology

Dermatology, Yale School of Medicine

Dermatology
PO Box 208030
New Haven, CT 06520-8030

Richard L. Edelson, M.D.

Richard L. Edelson, M.D.

Professor and Chairman, Dermatology
Director, Yale Comprehensive Cancer Center

Transimmunization Therapy

Cancer Treatment using Photopheresis graduates to a whole new level.

Research Interests

Cutaneous T cell lymphoma (CTCL), human T cell physiology, immunobiology of normal and diseased skin. Under the leadership of Dr. Edelson CTCL cells have been characterized and new and effective therapies developed. CTCL was found to be a cancer of "cutaneous T cells," which migrate to and infiltrate the skin. Dr. Edelson and his colleagues have developed an immunotherapy known as "Photopheresis," which is FDA approved and used to treat CTCL and other T cell mediated diseases in more than 100 centers worldwide.

Education:
 B.S. Hamilton College, 1966
M.D. Yale University School of Medicine, 1970
Training:
 Intern: University of Chicago
Resident: Massachusetts General Hospital
Senior Resident: Columbia Presbyterian Hospital

Selected Publications

  • Shofner JD, Vasquez JG, Berger CL, Edelson RL. Improved generation of anti-tumor immunity by antigen dose limitation. J Immune Based Ther Vaccines 5:2 doi: 10.11186/1476-8518, 2007.
  • Kuo PH, McClennan BL, Carlson K, Wilston LD, Edelson RL, Heald PW, Girardi M. FDG-PET/CT in the Evaluation of Cutaneous T-cell Lymphoma. Mol Imaging Biol 10.1007/s11307-007-1027, 2007.
  • Wong HK, Wilson AJ, Gibson HM, Hafner MS, Hedgcock C, Berger CL, Edelson RL, Lim HW. Increased Expression of CTLA-4 in PBMC and Malignant T-Cells from Patients with Mycocis Fungoides (CTCL). J. Invest Dermatol 126:212-219, 2006.
  • Nebozhyn M, Loboda A, Kari L, Rook AH, Vonderheid EC, Lessin S, Berger C, Edelson R, Nichols C, Yousef M. Gudipati L, Shang M, Showe MK, Showe LC. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5-99% circulating tumor cells with 90% accuracy. Blood 107:8 3189-3196, 2006.
  • Girardi M, Berger CL, Wilson LD, Christensen IR, Thompson KR, Glusac EJ, Edelson RL. Transimmunization for cutaneous T cell lymphoma: a Phase I study. Leuk Lymph 47:1495-1503, 2006.
  • Berger CL, Vasquez JG, Shofner J, Mariwalla K, Edelson RL. Langerhans cells: Mediators of immunity and tolerance. Int J Biochemistry & Cell Biology 38: 1632-1636, 2006.
  • Salskov-Iversen M, Berger CL, Edelson RL. Rapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading. Jrnl. Immune Based Therapies and Vaccines. 3:4, 2005.
  • Berger CL, Mariwalla K, Girardi M, Edelson RL. Advances in understanding the Immunobiology and immunotherapy of cutaneous T cell lymphoma. In Advances in Dermatology, Volume 20, Chapter 8, pp. 217-235, 2005.
  • Berger CL, Shofner J, Vasquez JG, Mariwalla K and Edelson RL. Cancer Immunotherapy. Cancer Therapy Vol. 3, pp 1-17, 2005.
  • Fletcher CL, Orchard GE, Hubbard V, Whittaker SJ, Edelson RL, Russell-Jones R. CD30+ Cutaneous Lymphoma in Association with Atopic Eczema. Arch Dermatol. 140: 449-454, 2004.
  • Berger CL and Edelson R. The Life Cycle of Cutaneous T Cell Lymphoma Reveals Opportunities for Targeted Drug Therapy. In Current Cancer Drug Targets. 4:609-619, 2004.
  • Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, Edelson RL. Cutaneous T cell lymphoma, malignant proliferation of T-regulatory cells. Blood. 105:1640-1647, 2004.
  • Berger CL, Edelson RL. Current Concepts of the Immunobiology and Immunotherapy of Cutaneous T Cell Lymphoma: Insights Gained through Cross-talk between the Clinic and the Bench. Leukemia & Lymphoma. 44(10): pp. 1697-1703, 2003.
  • Girardi, M, Knobler R, Edelson R. Selective immunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow. Hematology/Oncology Clinics of North America, 17/6, p. 1391-1401, 2003.
  • Berger CL, Hanlon D, Kanada D, Dhodapkar M, Lombillo V, Wang N, Christensen I, Howe G, Crouch J, El-Fishawy P, Edelson R. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood, Vol.99: 8-2929-2939, 2002.
  • Edelson RL. Editorial. Transimmunization: the science catches up to the clinical success. Transfusion and Apheresis Science, 26: 177-180, 2002.
  • Berger CL, Hanlon D, Kanada D, Girardi M, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. Transfusion and Apheresis Science, 26: 205-216, 2002.
  • Girardi M, Berger C, Hanlon D, Edelson RL. Efficient Tumor Antigen Loading of dendritic Antigen Presenting Cells by Transimmunization. Technology in Cancer Research and Treatment. 1:1: 65-69, 2002.
  • Berger CL, Xu AL, Hanlon D, Lee C, Schechner J, Glusac E, Christensen I, Snyder E, Holloway V, Tigelaar R, and Edelson RL. Induction of Human Tumor-Loaded Dendritic Cells. Int J Cancer 91: 438-447, 2002.
  • Edelson RL. Cutaneous T Cell Lymphoma: The Helping Hand of Dendritic Cells. Annals NY Acad Science. Vol 941, 1-11, 2002.
  • Meech SJ, Edelson R, Walsh P, Norris DA, Duke RC. Reversible Resistance to Apoptosis in Cutaneous T Cell Lymphoma. Annals NY Acad Science, Vol. 941: 46-58, 2002.
  • Berger CL, Longley J, Hanlon D, Girardi M and Edelson R. The Clonotypic T Cell Receptor is a Source Tumor-associated Antigens in Cutaneous T Cell Lymphomas. Annals NY Acad Science, Vol. 941: 106-122, 2002.
  • Jillilla AP, Murren JR, Hamid KK, Longley BJ, Edelson RL, Cooper DL. P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. Cancer Invest. 18(7): 609-13, 2000.
  • Edelson, Richard L. Pemphigus - Decoding the Cellular Language of Cutaneous Autoimmunity. Editorial New Engl J Med, 343: 60--61, 2000.
  • Girardi M. Edelson RL. Cutaneous T-Cell Lymphoma: Pathogenesis and Treatment. Oncology 14:7 1061-1069, 2000.
  • Edelson, Richard L. Pemphigus - Decoding the Cellular Language of Cutaneous Autoimmunity. Editorial New Engl J Med, 343: 60-61, 2000.
  • Girardi M. Edelson RL. Cutaneous T-Cell Lymphoma: Pathogenesis and Treatment. Oncology 14:7 1061-1069, 2000.
  • Berger CL, Xu AL, Hanlon D, Lee C, Schechner J, Glusac E, Christensen I, Snyder E, Holloway V, Tigelaar R, Edelson RL. Transimmunication: Transfer of the Full Array of Human Tumor Antigens to Dendritic Antigen Presenting Cells for Use in Anti-Tumor Vaccination. Submitted, 2000.
  • Schechner JS, Edelson RL, McNiff JM, Heald PW, Pober JS. Expression of Integrin a4Û7 on epidermotropic cutaneous T cells in cutaneous T cell lymphoma and spongiotic dermatitis. Lab Invest 79:601-607, 1999.
  • Heald PW and Edelson RL. Cutaneous T Cell Lymphoma. In: Malignant Tumors of the Skin. Chu AC and Edelson RL, eds. Edward Arnold Publishers, London, pp. 138-145, 1999
  • Edelson RL and Berger C. Extracorporeal photochemotherapy. In: Malignant Tumors of the Skin. Chu AC and Edelson RL, eds. Edward Arnold Publishers, London, pp. 396-408, 1999.
  • Edelson RL. Cutaneous T-Cell Lymphoma: A Model for Selective Immunotherapy. The Cancer Journalfrom Scientific American. Volume 4 (2): 62-71, 1998.
  • Hanlon D, Berger C, and Edelson RL. 8-Methoxypsoralen-Driven Increases in MHC Class I Associated Cell Surface Antigens. In Press Int J of Cancer, 1998.
  • Berger CL, Longley BJ, Imaeda S, Christensen I, Heald P, Edelson RL. Tumor-specific peptides in cutaneous T-cell lymphoma: Association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int J Cancer 76:304-311, 1998.
  • Hanlon D, Berger C, Edelson RL. Photoactivated 8-Methoxypsoralen causes a peptide-dependent increase in antigen display by transformed lymphocytes. Int J Cancer 78:70-75, 1998.
  • Edelson RL. Cutaneous T-Cell Lymphoma: A Model for Selective Immunotherapy. The Cancer Journal from Scientific American. Volume 4 (2): 62-71, 1998.
  • Berger CL, Dong Z, Hanlon DJ, Bisaccia E, Edelson RL. A lymphocyte cell surface heat shock protein homologous to the endoplasmic reticulin chaperone, immunoglobulin heavy chain binding protein BIP. Int J Cancer 71: 1077-85, 1997.
  • Wilson LD, Jones GW, Kim D, Rosenthal D, Christensen I, Edelson RL, Heald PW, Kacinski BM. The Influence of Extracorporeal Photopheresis (ECP) in Addition to Total Skin Electron (TSE) Therapy on Disease-Free and Cause-Specific Survival in Patients with Erythrodermic (T4) Mycosis Fungoides (MF) and The Sezary Syndrome. Submitted 1997.
  • Wilson LD, Kacinski BM, Edelson RL, Heald PW. Cutaneous T-Cell Lymphomas Cancer: Principles & Practice of Oncologv edited by Vincent T. DeVita, Jr., MD, Samuel Hellman, MD, Steven A. Rosenberg, MD, PhD. Chapter 44(4):2220-2232, 1997.
  • Bolognia JL, Edelson RL. Spread of antibiotic-resistant bacteria from acne patients to personal contacts - a problem beyond the skin? The Lancet editorial, David Frankel Editor. 350:972-973, 1997.
  • Fargnoli MC, Edelson RL, Chimenti S. Couture C, Mustelin T. Halaban R. Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70,Syk and membrane-associated Csk. Leukemia 11: 1338-1346, 1997.
  • Quiros PA, Jones GW, Kacinski BM, Heald P. Edelson R. Braverman I, Wilson LD. Total Skin Electron Beam Therapy Followed by Adjuvant Psoralen / Ultraviolet A Light in the Management of Patients with T1 and T2 Cutaneous T-Cell Lymphoma (Mycosis Fungoides). Int J Radiation Oncology Biol Phy 38(5): 1027-1035, 1997.
  • Wilson LD, Quiros PA, Kolenik SA, Heald PW, Braverman IM, Edelson RL & Kacinski BM.  Additional courses of  total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma.  J Amer Acad Derm 35: 69-73, 1996.
  • Imaeda S. Felli A, Schmitt I, Chimenti S. and Edelson RL. Induction of Functional Empty Class I Major Histocompatibility Complex Glycoproteins by Photoactivated 8-Methoxypsoralen. J Invest Dermatol 107:887-890, 1996.
  • Berger C, Wang N. Christensen I, Longley J. Heald P. Edelson RL. The immune response to class I associated tumor-specific cutaneous T cell lymphoma antigens. J Invest Dermatol 107:392-397, 1996.
  • Wilson LD, Quiros PA, Kolenik SA, Heald PW, Braverman IM, Edelson RL & Kacinski BM. Additional Courses of Total Skin Electron Beam Therapy in the Retreatment of Patients with Cutaneous T-cell Lymphoma. J Amer Acad Derm 35:69-73, 1996.
  • Berger CL, Liu W. Christensen I, Heald P. Edelson RL. The immune response to class I associated tumor-specific cutaneous T cell lymphoma peptide antigens. Submitted Cancer 1995.
  • Longley J. Tyrrell L, Lu, S-Z, Farrell J. Ding T. Yan S. Sallee D, Heald P. Berger C, Tigelaar R. Edelson R. Malignant and Normal T Cells Show Random Use of T-cell Receptor oo Chain Variable Regions in Patients with Cutaneous T-cell Lymphoma. J Invest Dermatol 105:62-64, 1995.
  • Wilson LD, Licata AL, Braverman IM, Edelson RL, Heald PW, Feldman AM, Kacinski BM. Systemic chemotherapy and extracorporeral photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Rad Oncol 32:987-995, 1995.
  • Heald PW, Kim HY, Perez M, Edelson R. Berger CL. T-cell responses in Photoimmune therapy. I ClinApheresis, 10:144-149, 1995.
  • Wilson LD, Quiros P. Braverman IM, Edelson R. Heald PW, Ehrnstrom PG, Kacinski BM. Impact of Prognostic Factors, Adjuvant Therapies and Retreatment on CTCL Patients Treated with TSEBT. Proceedings of the American Radium Society 78th Annual Meeting, p. 24, Paris, France, April 29May 3, 1995.
  • Perez MI, Edelson RL. Regulation of Immunity by Ultraviolet Radiation and Photosensitized Reactions. Chemical Immun 58: 314-330, 1994.
  • Tokura Y. Yagi J. O'Malley M, Lewis JM, Takigawa M, Edelson RL and Tigelaar RE. Superantigenic Staphyloccal Exotoxins Induce T-Cell Proliferation in the presence of Langerhans Cells or Class IIBearing keratinocytes and stimulate keratinocytes to produce T-cell-activating cytokines. JID 102: 31-38, 1994.
  • Edelson RL, Perez M, Heald P. Berger C. Extracorporeal Photochemotherapy. Biologic Therapy of Cancer, J.B. Lippincott Co., V. DeVita, S. Hellman, S. Rosenberg, Editors. 4,:1-10, 1994.
  • Schmitt IM, Maxwell VM, Olack GA, Edelson RL, Chimenti S. Gasparro FP. The specific effects of 8-methoxypsoralen photoadducts on cell growth: HPLC analysis of monoadduct and crosslink formation in cells exposed to split-dose treatment. J Photochem and Photobiol B: Biol., 22: 17-21, 1994.
  • Heald P. Yan SL, Latkowski J. Edelson R. Profound deficiency in normal and circulating T-cells in erythrodermic cutaneous T-cell lymphoma. Arch Dermatol 130: 198-203, 1994.
  • Heald PW, Yan SL, Edelson RL, Tigelaar R. Picker LJ. Skin-Selective Lymphocyte Homing Mechanisms in the Pathogenesis of Leukemic Cutaneous T-Cell Lymphoma. lD 101 :222-26, 1993.
  • Frieden TR, Bia FJ, Heald PW, Eisen RN, Patterson TF, and Edelson RL. Cutaneous cryptococcosis in a patient with cutaneous T cell lymphoma receiving therapy with photopheresis and methotrexate. Clin. Inf. Dis. 17:776-778, 1993.
  • Tokura Y. Edelson RL, Gasparro FP. Modulation of 8-Methoxypsoralen-DNA Photoadduct Formation by Cell differentiation, mitogenic stimulation and phorbol ester exposure in murine T lymphocytes. Photochem and Photobiol. 58:6: 822-826, 1993.
  • Ding TG, Qiu BS, Kolenik SA, Yan SL, Wang XM, Longley BJ, Edelson RL. Effect of granulocyte macrophage colony-stimulating factor on mixed lymphocyte-epidermal cell culture. J Chinese Dermatology25(2): 88-90, 1992.

Review Articles and Chapters

  • Heald PW and Edelson RL. Cutaneous T Cell Lymphoma. In: Malignant Tumors of the Skin. Chu AC and Edelson RL, eds. Edward Arnold Publishers, London, pp. 138-145, 1999.
  • Edelson RL. Extracorporeal Photochemotherapy: Cellular Therapy for Cutaneous T-Cell Lymphoma, Selected Autoimmune Disorders, and Organ Transplant Rejection. Therapeutic Immunologv edited by Drs. Austen, Burakoff, Rosen and Strom. Chapter 50:615-627, 1996.
  • Heald, PW, Shapiro PE, Madison JF, Leboit PE, Edelson R. Cutaneous T-Cell Lymphoma: Relevant Scientific Summary of Neoplastic T-Cells: Classic Disease Description and Pathology. Cutaneous Medicine and Surgerv, Kenneth Arndt, Philip LeBoit, June Robinson, and Bruce U. Wintroub, Eds. 158:1639-1659, 1995.
  • Gasparro FP and Edelson RL . Extracorporeal Photo chemotherapy. Photoimmuno logv. Jean Krutmann and Craig A. Elmets, Eds. 17:231-245, 1995.
  • Lim H. Edelson RL. Photopheresis for the Treatment of Cutaneous T-cell Lymphoma. Monograph. Hematol Oncol Clin North Am Howard K. Koh, Francine M. Foss, Guest Editors. Vol. 9(5) 111726, 1995.
  • Smith RW, Blaese RM, Hatchcock KS, Buell DN, Edelson RL and Lutzner MA.  T and B lymphocyte markers in lymphoid cell research and in human diseases in Lymphocyte Recognition and Effector Mechanisms:  Proceedings of the Eighth Leukocyte Culture Conference.  Academic Press (New York), pages 127-132, 1974.

Books

  • Edelson, R. and DeVita VT. Cutaneous T Cell Lymphoma: Basic and Clinically Relevant Biology. Annals NY Acad Science, Vol. 941, 2002.
  • Edelson, Richard L. Editor, Transfusion and Apheresis Science. Vol. 26 Issue 3, June 2002.
  • Edelson RL and Chu AC (Editors). Malignant Tumors of the Skin - Edward Arnold Publishers, London, 1999.
  • Heald PW, Edelson RL. Cutaneous Lymphomas. In: Dermatology in General Medicine, Fitzpatrick TB et al (eds) 1998.
  • Edelson R. Antigen and Clone-Specific Immunoregulation. Editor, Annals NY Acad Science, Volume 636, 1991.
  • Milstone L and Edelson R. Endocrine metabolic and immunologic functions of keratinocytes. Annals NY Acad Science, Volume 548, 1988.

 

Contact

Campus Address
Yale School of Medicine
333 Cedar Street LCI 501
New Haven, CT 06520-8059

Phone
(203) 785-4091

Email
redelson@yale.edu